Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.00% | -23.67% | -31.36% | -51.05% | -45.44% |
| Total Depreciation and Amortization | 3.27% | 2.61% | 1.63% | 0.98% | -1.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.96% | 20.46% | 34.16% | 60.85% | 36.41% |
| Change in Net Operating Assets | 75.54% | 237.86% | 3,720.57% | 771.63% | 330.89% |
| Cash from Operations | 7.16% | -18.93% | -20.95% | -37.43% | -35.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.26% | 256.18% | 232.08% | 272.21% | 177.03% |
| Cash from Investing | 29.22% | 256.14% | 232.04% | 272.17% | 177.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -44.23% | -99.46% | -99.60% | -99.27% | -98.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 82.70% |
| Cash from Financing | -33.08% | -99.45% | -99.59% | -99.26% | -98.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.79% | -164.85% | 134.53% | -96.64% | -57.39% |